- Home
- SDSTW vs JAGX Comparison
SDSTW vs JAGX Comparison
Compare SDSTW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDSTW
- JAGX
- Stock Information
- Founded
- SDSTW N/A
- JAGX 2013
- Country
- SDSTW United States
- JAGX United States
- Employees
- SDSTW 8
- JAGX N/A
- Industry
- SDSTW
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- SDSTW
- JAGX Health Care
- Exchange
- SDSTW Nasdaq
- JAGX Nasdaq
- Market Cap
- SDSTW 2.9M
- JAGX 3.4M
- IPO Year
- SDSTW N/A
- JAGX N/A
- Fundamental
- Price
- SDSTW $0.09
- JAGX $2.24
- Analyst Decision
- SDSTW
- JAGX Strong Buy
- Analyst Count
- SDSTW 0
- JAGX 1
- Target Price
- SDSTW N/A
- JAGX $60.00
- AVG Volume (30 Days)
- SDSTW 41.6K
- JAGX 99.7K
- Earning Date
- SDSTW 03-26-2025
- JAGX 08-12-2025
- Dividend Yield
- SDSTW N/A
- JAGX N/A
- EPS Growth
- SDSTW N/A
- JAGX N/A
- EPS
- SDSTW N/A
- JAGX N/A
- Revenue
- SDSTW N/A
- JAGX $11,552,000.00
- Revenue This Year
- SDSTW N/A
- JAGX $22.41
- Revenue Next Year
- SDSTW N/A
- JAGX $30.00
- P/E Ratio
- SDSTW N/A
- JAGX N/A
- Revenue Growth
- SDSTW N/A
- JAGX 13.93
- 52 Week Low
- SDSTW $0.10
- JAGX $2.19
- 52 Week High
- SDSTW $0.12
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- SDSTW N/A
- JAGX 29.03
- Support Level
- SDSTW N/A
- JAGX $2.32
- Resistance Level
- SDSTW N/A
- JAGX $2.79
- Average True Range (ATR)
- SDSTW 0.00
- JAGX 0.14
- MACD
- SDSTW 0.00
- JAGX 0.08
- Stochastic Oscillator
- SDSTW 0.00
- JAGX 8.33
About SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.